Benefits of lifestyle modification in NAFLD.
作者信息
Harrison Stephen A, Day Christopher Paul
机构信息
Gastroenterology and Hepatology Division, Brooke Army Medical Center, Fort Sam, Houston, TX, USA.
出版信息
Gut. 2007 Dec;56(12):1760-9. doi: 10.1136/gut.2006.112094. Epub 2007 Oct 2.
Abstract
摘要
相似文献
1
Benefits of lifestyle modification in NAFLD.
Gut. 2007 Dec;56(12):1760-9. doi: 10.1136/gut.2006.112094. Epub 2007 Oct 2.
2
Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?
World J Gastroenterol. 2012 Dec 14;18(46):6790-800. doi: 10.3748/wjg.v18.i46.6790.
3
Non-alcoholic fatty liver disease and insulin resistance.
Eur J Gastroenterol Hepatol. 2005 Aug;17(8):823-6. doi: 10.1097/00042737-200508000-00008.
4
Physical activity: an essential component of lifestyle modification in NAFLD.
Nat Rev Gastroenterol Hepatol. 2012 Dec;9(12):726-31. doi: 10.1038/nrgastro.2012.200. Epub 2012 Oct 23.
5
[Treatment of NASH: nutritional counseling and physical exercise].
Nihon Rinsho. 2006 Jun;64(6):1139-45.
6
[Pathogenesis and treatment of non-alcoholic fatty liver disease].
Zhong Xi Yi Jie He Xue Bao. 2010 Mar;8(3):201-9. doi: 10.3736/jcim20100301.
7
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.
Hepatology. 2008 Jul;48(1):119-28. doi: 10.1002/hep.22336.
8
Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options.
Curr Vasc Pharmacol. 2012 Mar;10(2):162-72. doi: 10.2174/157016112799305012.
9
Treatment of non-alcoholic fatty liver disease.
J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:79-80. doi: 10.1111/jgh.12242.
10
Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children.
World J Gastroenterol. 2008 Mar 14;14(10):1598-602. doi: 10.3748/wjg.14.1598.
引用本文的文献
1
Long-Term Aerobic Exercise Enhances Hepatoprotection in MAFLD by Modulating Exosomal miR-324 via ROCK1.
Metabolites. 2024 Dec 9;14(12):692. doi: 10.3390/metabo14120692.
2
Dietary insulin index and dietary insulin load in relation to non-alcoholic fatty liver disease: a cross-sectional study.
Public Health Nutr. 2024 Sep 26;27(1):e182. doi: 10.1017/S1368980024001149.
3
Exploring the Impact of Astaxanthin Supplementation in Conjunction with a 12-Week CrossFit Training Regimen on Selected Adipo-Myokines Levels in Obese Males.
Nutrients. 2024 Aug 26;16(17):2857. doi: 10.3390/nu16172857.
4
Machine learning uncovers manganese as a key nutrient associated with reduced risk of steatotic liver disease.
Liver Int. 2024 Oct;44(10):2807-2821. doi: 10.1111/liv.16055. Epub 2024 Jul 31.
5
Circulating microRNAs as potential biomarkers of physical activity in geriatric patients with HCV.
BMC Mol Cell Biol. 2024 Jul 19;25(1):18. doi: 10.1186/s12860-024-00514-8.
6
Combined Exercise and Diet Induce Airway Hyperreactivity While Reducing Liver Steatosis in Mice with Diet-Induced Obesity.
Nutrients. 2024 Jul 3;16(13):2129. doi: 10.3390/nu16132129.
7
Optimized Sugar-Free Citrus Lemon Juice Fermentation Efficiency and the Lipid-Lowering Effects of the Fermented Juice.
Nutrients. 2023 Dec 13;15(24):5089. doi: 10.3390/nu15245089.
8
Protection of Liver Functions and Improvement of Kidney Functions by Twelve Weeks Consumption of Cuban Policosanol (Raydel) with a Decrease of Glycated Hemoglobin and Blood Pressure from a Randomized, Placebo-Controlled, and Double-Blinded Study with Healthy and Middle-Aged Japanese Participants.
Life (Basel). 2023 Jun 4;13(6):1319. doi: 10.3390/life13061319.
9
Ginsenoside Rg3-enriched Korean Red Ginseng extract attenuates Non-Alcoholic Fatty Liver Disease by way of suppressed VCAM-1 expression in liver sinusoidal endothelium.
J Ginseng Res. 2023 May;47(3):429-439. doi: 10.1016/j.jgr.2022.10.005. Epub 2022 Oct 27.
10
Association of Healthy Lifestyles with Non-Alcoholic Fatty Liver Disease: A Prospective Cohort Study in Chinese Government Employees.
Nutrients. 2023 Jan 24;15(3):604. doi: 10.3390/nu15030604.
本文引用的文献
1
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Physiol Rev. 2007 Apr;87(2):507-20. doi: 10.1152/physrev.00024.2006.
2
Impact of weight loss on the metabolic syndrome.
Int J Obes (Lond). 2007 Sep;31(9):1442-8. doi: 10.1038/sj.ijo.0803606. Epub 2007 Mar 13.
3
Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial.
JAMA. 2007 Mar 7;297(9):969-77. doi: 10.1001/jama.297.9.969.
4
Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats.
Hepatology. 2007 Mar;45(3):778-88. doi: 10.1002/hep.21499.
5
Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease.
J Clin Invest. 2007 Mar;117(3):739-45. doi: 10.1172/JCI30400. Epub 2007 Feb 22.
6
Nonalcoholic fatty liver disease in severely obese subjects.
Am J Gastroenterol. 2007 Feb;102(2):399-408. doi: 10.1111/j.1572-0241.2006.01041.x.
7
AMP-activated protein kinase in metabolic control and insulin signaling.
Circ Res. 2007 Feb 16;100(3):328-41. doi: 10.1161/01.RES.0000256090.42690.05.
8
The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study.
Dig Dis Sci. 2007 Feb;52(2):589-93. doi: 10.1007/s10620-006-9433-5. Epub 2007 Jan 12.
9
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
N Engl J Med. 2006 Nov 30;355(22):2297-307. doi: 10.1056/NEJMoa060326.
10
Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo.
FASEB J. 2007 Jan;21(1):53-60. doi: 10.1096/fj.06-6557com. Epub 2006 Nov 10.
Zotero 插件